NGAL for reduction and amelioration of ischemic and nephrotoxic injuries

摘要

Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeuticand in a method of treating, reducing, or ameliorating an injury selected froman ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury,to an organ in a patient. The invention includes administering to the patientNGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion,or toxin-induced injury to the organ, such as the kidney. A siderophore can beco-administered with the NGAL. The invention also relates to administeringa sideophore to enhance a response to secretion of NGAL following an ischemicor toxin-induced injury to an organ in a patient.